Please review the Brintellix Approved Product Information before prescribing. Product Information is available by calling Lundbeck on 1300 721 277.
I feel worthless 1
I keep forgetting things 1
I always feel tired 1
I can’ t concentrate 1
Enable patients to not only feel better, but to think and function better * 2−7
* Brintellix displayed efficacy on depressive symptoms( MADRS, HAM-D 24
) and improved cognitive symptoms( DSST, RAVLT, UPSA) of major depressive disorder vs. placebo 2-7
DSST: Digit Symbol Substitution Test; HAM-D 24
: 24-item Hamilton Depression Scale; MADRS: Montgomery-Åsberg Depression Rating Scale; RAVLT: Rey Auditory Verbal Learning Test; UPSA: University of San Diego Performance-Based Skills Assessment.
PBS Information: This product is not listed on the PBS.
Please review the Brintellix Approved Product Information before prescribing. Product Information is available by calling Lundbeck on 1300 721 277.
Minimum Product Information: Brintellix( vortioxetine hydrobromide). Indications: Treatment of major depressive disorder in adults including prevention of relapse. Vortioxetine is not indicated for paediatric use. Dosage & Administration: To be taken with or without food. Adults: 10 mg once daily; depending on individual response maximum 20 mg once daily or reduced to 5 mg once daily. Elderly(> 65 years): 5 mg once daily; increase to 10 mg once daily if required. Dosage adjustment may be required for strong CYP2D6 inhibitors or CYP450 inducers. Treatment for at least 6 months is recommended for consolidation of response. Contraindications: Hypersensitivity to any component of Brintellix ®. Concomitant treatment with MAOIs or treatment within 14 days of MAOIs. Precautions: Clinical worsening and suicide risk; Neuroleptic Malignant Syndrome; Serotonin Syndrome; activation of mania / hypomania; seizures; haemorrhage; hyponatraemia; severe hepatic impairment; severe renal impairment; pregnancy( Category B3); electroconvulsive therapy; breastfeeding is not recommended. Interactions: MAOIs( see full PI for details); serotonergic medicines including tramadol and triptans; St John’ s Wort; CYP450 inducers e. g. rifampicin; CYP450 inhibitors e. g. bupropion; antiplatelets; anticoagulants; lithium; tryptophan; medicines lowering the seizure threshold including SSRIs, SNRIs, tricyclics, neuroleptics, mefloquine, tramadol. Adverse Effects: nausea; vomiting; diarrhoea; constipation; decreased appetite; sedation; generalised pruritus. For all other adverse events see full PI. Date of TGA approval: 31 March 2014. Date of Minimum PI: 26 September 2014.
References: 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: American Psychiatric Publishing, 2013. 2. Brintellix ® Australian Approved Product Information. 3. Alvarez E et al. Int J Neuropsychopharmacol 2012; 15( 5): 589 – 600. 4. Katona C et al. Int Clin Psychopharmacol 2012; 27( 4): 215 – 223. 5. Montgomery SA et al. Hum Psychopharmacol Clin Exp 2014; 29( 5): 470 – 482. 6. McIntyre RS et al. Int J Neuropsychopharmacol 2014; 17( 10): 1557 – 1567. 7. Mahableshwarkar AR et al. Neuropsychopharmacology 2015; 40( 8): 2025 – 2037.
Lundbeck Australia Pty Ltd ABN 86 070 094 290. Ground Floor, 1 Innovation Road, North Ryde NSW 2113. Ph: + 61 2 8669 1000. Fax: + 61 2 8669 1090. Medical Information: 1300 721 277. 904960. Prepared July 2017. SM _ LUN735b.